Literature DB >> 20943609

Chronic lymphocytic leukemia.

Michael Hallek1, Natali Pflug.   

Abstract

The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central pathways regulating the cell cycle, the apoptotic machinery, or the leukemic microenvironment (flavopiridol, oblimersen, ABT-263 or lenalidomide) are being tested in clinical trials. Furthermore, improved protocols using reduced-intensity allogeneic progenitor cell transplantation makes it possible to offer this procedure to more patients with CLL. Finally, new prognostic markers that may influence therapeutic decisions have been identified. This review attempts to summarize the current knowledge in this rapidly moving field.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20943609     DOI： 10.1093/annonc/mdq373

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  17 in total

Review 1.  What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

Authors:  Benjamin N Voorhies; Deborah M Stephens
Journal:  Curr Treat Options Oncol       Date:  2017-02

Review 2.  High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.

Authors:  T Reljic; A Kumar; B Djulbegovic; M A Kharfan-Dabaja
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

3.  Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

Authors:  Bang-Ning Lee; Hui Gao; Evan N Cohen; Xavier Badoux; William G Wierda; Zeev Estrov; Stefan H Faderl; Michael J Keating; Alessandra Ferrajoli; James M Reuben
Journal:  Cancer       Date:  2011-02-24       Impact factor: 6.860

4.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

5.  Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

Authors:  Alexander N Wein; Shihui Liu; Yi Zhang; Andrew T McKenzie; Stephen H Leppla
Journal:  Invest New Drugs       Date:  2012-07-28       Impact factor: 3.850

6.  Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.

Authors:  Loretta J Nastoupil; Christopher R Flowers
Journal:  Community Oncol       Date:  2012-12

7.  Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.

Authors:  Susan M O'Brien; Samantha Jaglowski; John C Byrd; Rajat Bannerji; Kristie A Blum; Christopher P Fox; Richard R Furman; Peter Hillmen; Thomas J Kipps; Marco Montillo; Jeff Sharman; Sam Suzuki; Danelle F James; Alvina D Chu; Steven E Coutre
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

8.  Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.

Authors:  Ashiq Masood; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancers (Basel)       Date:  2011-06-01       Impact factor: 6.639

Review 9.  Targeting ATM-deficient CLL through interference with DNA repair pathways.

Authors:  Gero Knittel; Paul Liedgens; Hans C Reinhardt
Journal:  Front Genet       Date:  2015-06-10       Impact factor: 4.599

Review 10.  Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.

Authors:  Kanti R Rai
Journal:  J Hematol Oncol       Date:  2015-07-14       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.